Atyr Pharma, Inc.

Pangu Biopharma Limited

Applied Molecular Evolution

Buck Institute for Research on Aging

Unity Biotechnology, Inc.

Mayo Foundation for Medical Education and Research

Geron Corporation

Janssen Biotech, Inc.

The Johns Hopkins University

Eli Lilly and Company

Kythera Biopharmaceuticals, Inc.

Other

Centocor, Inc.

Centocor Ortho Biotech Inc.

Atye Pharma, Inc.

Alain Philippe Vasserot

Jeffry Dean Watkins

Leslie Ann Greene

Kyle P Chiang

Fei Hong

John D Mendlein

Cheryl L Quinn

Wing-Sze Lo

David Matthew Marquis

Nathaniel E David

Remi-Martin Laberge

David M Knight

Raymond W Sweet

David J Shealy

Sheng-Jiun Wu

Judith Campisi

Jing Yang

James L Kirkland

Tamar Tchkonia

Vedrana Stojanovic-Susulic

Yi Zhu

Eric Michael Smith

Bailin Liang

Serge P Lichtsteiner

Debra Gardner

Michael W Lark

Yan Chen

Susan H Tam

Marco Demaria

Jan M A Van Deursen

Bennett G Childs

Scott L Weinrich

Ronald A Pruzan

Darren J Baker

Edward M Atkinson, Iii

Ryan Andrew Adams

Xiao-Yu R Song

Xiao-yu R Song

Wei Zhang

Jennifer H Elisseeff

Kristi Helen Piehl

Albert Davalos

Alina He

Okhee Jeon

Chaekyu Kim

Craig Duane Dickinson

Zhiwen Xu

William D Huse

William H Andrews

Gregg B Morin

Jirong Lu

Catherine Brautigam Beidler

James T Kealey

Robert R Adams

Kristine Kay Kikly

Derrick Ryan Witcher

Ying Buechler

Jeffrey D Watkins

Chi-Fang Wu

Stuart W Bright

Minh-Ha Do

Rajesh Belani

Neil Poloso

Susan Tam

Yan Chan

This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.

Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor

Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

Anti-IL-6 antibody

Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor

Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye

Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase

Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof.

Immunogenic compositions for inducing an immune response for elimination of senescent cells

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases

Growing community of inventors

Carlsbad, CA, United States of America

Alain Philippe Vasserot